{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:01:15Z","timestamp":1768410075475,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.puhe.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T20:03:30Z","timestamp":1474056210000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences"],"prefix":"10.1016","volume":"141","author":[{"given":"T.","family":"Ward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-2652","authenticated-orcid":false,"given":"S.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sugrue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.puhe.2016.08.002_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"issue":"4","key":"10.1016\/j.puhe.2016.08.002_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.puhe.2016.08.002_bib3","article-title":"Clinical practice guidelines: EASL recommendations on treatment of hepatitis C 2015","volume":"62","author":"European Association For The Study Of The Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.puhe.2016.08.002_bib4","series-title":"Data tables of the unlinked anonymous monitoring survey of HIV and hepatitis in people who inject drugs","author":"Public Health England","year":"2013"},{"issue":"s1","key":"10.1016\/j.puhe.2016.08.002_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2893.2004.00570.x","article-title":"Who is at risk and how do we identify them?","volume":"11","author":"Goldberg","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.puhe.2016.08.002_bib6","series-title":"Health Protection Scotland, Public Health Wales, Public Health Agency. Hepatitis C in the UK: 2015 report","author":"Public Health England","year":"2015"},{"issue":"7","key":"10.1016\/j.puhe.2016.08.002_bib7","doi-asserted-by":"crossref","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention","volume":"9","author":"Wiessing","year":"2014","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.puhe.2016.08.002_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jvh.12338","article-title":"HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact","volume":"22","author":"Martin","year":"2014","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.puhe.2016.08.002_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.puhe.2016.08.002_bib10","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"issue":"9956","key":"10.1016\/j.puhe.2016.08.002_bib11","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"9916","key":"10.1016\/j.puhe.2016.08.002_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.puhe.2016.08.002_bib13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/gutjnl-2014-308166","article-title":"Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?","volume":"64","author":"Innes","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.puhe.2016.08.002_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.26304","article-title":"The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States","volume":"58","author":"McEwan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.puhe.2016.08.002_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.vhri.2013.08.001","article-title":"Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection","volume":"3","author":"McEwan","year":"2013","journal-title":"Value Health Regional Issues"},{"issue":"1","key":"10.1016\/j.puhe.2016.08.002_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40258-012-0002-0","article-title":"Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model","volume":"11","author":"McEwan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.puhe.2016.08.002_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vhri.2014.04.005","article-title":"Estimating the long-term clinical and economic outcomes of Daclatasvir plus Asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis C genotype 1b","volume":"3","author":"McEwan","year":"2014","journal-title":"Value Health Regional Issues"},{"issue":"1","key":"10.1016\/j.puhe.2016.08.002_bib18","doi-asserted-by":"crossref","first-page":"e0117334","DOI":"10.1371\/journal.pone.0117334","article-title":"Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C","volume":"10","author":"McEwan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.puhe.2016.08.002_bib19","first-page":"82","article-title":"Backcalculation of HIV infection rates","author":"Bacchetti","year":"1993","journal-title":"Stat Sci"},{"issue":"8","key":"10.1016\/j.puhe.2016.08.002_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2893.2007.00851.x","article-title":"The burden of hepatitis C in England","volume":"14","author":"Sweeting","year":"2007","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.puhe.2016.08.002_bib21","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/hep.510290528","article-title":"Modeling the hepatitis C virus epidemic in France","volume":"29","author":"Deuffic","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.puhe.2016.08.002_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.drugalcdep.2007.05.026","article-title":"Modelling the hepatitis C virus epidemic in Australia","volume":"91","author":"Razali","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"10.1016\/j.puhe.2016.08.002_bib23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/sim.4780101005","article-title":"A method of non-parametric back-projection and its application to AIDS data","volume":"10","author":"Becker","year":"1991","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.puhe.2016.08.002_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/sim.4780080105","article-title":"Statistical methods for short-term projections of AIDS incidence","volume":"8","author":"Brookmeyer","year":"1989","journal-title":"Stat Med"},{"issue":"1226","key":"10.1016\/j.puhe.2016.08.002_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1098\/rstb.1989.0076","article-title":"Estimation of the incidence of HIV infection","volume":"325","author":"Isham","year":"1989","journal-title":"Philosophical Trans R Soc Lond Biol Sci"},{"key":"10.1016\/j.puhe.2016.08.002_bib26","unstructured":"UK office for National Statistics. England and Wales life tables: 1980\u201382 to 2012\u20132014. Available from: http:\/\/www.ons.gov.uk\/ons\/taxonomy\/index.html?nscl=Life+Tables-tab-data-tables. (last accessed 16 October 2015)."},{"issue":"1","key":"10.1016\/j.puhe.2016.08.002_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"Martin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.puhe.2016.08.002_bib28","series-title":"Hepatits C in the UK: 2014 report","author":"Public Health England","year":"2014"},{"issue":"12","key":"10.1016\/j.puhe.2016.08.002_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2893.2007.00876.x","article-title":"Comparison of deaths related to hepatitis C and AIDS in Scotland","volume":"14","author":"Palmateer","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.puhe.2016.08.002_bib30","series-title":"European drug report 2014","author":"European Monitoring Centre for Drugs and Drug additicon","year":"2015"},{"issue":"2","key":"10.1016\/j.puhe.2016.08.002_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.puhe.2016.08.002_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2893.2005.00630.x","article-title":"Polymorphisms of the renin\u2013angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection","volume":"12","author":"Forrest","year":"2005","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.puhe.2016.08.002_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2893.2003.00454.x","article-title":"Improved detection of hepatocyte proliferation using antibody to the pre-replication complex: an association with hepatic fibrosis and viral replication in chronic hepatitis C virus infection","volume":"10","author":"Freeman","year":"2003","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.puhe.2016.08.002_bib34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1468-1293.2005.00291.x","article-title":"Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London","volume":"6","author":"Mohsen","year":"2005","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.puhe.2016.08.002_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gut.2003.021691","article-title":"Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study","volume":"53","author":"Ryder","year":"2004","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.puhe.2016.08.002_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2893.1997.00054.x","article-title":"Importance of age in chronic hepatitis C virus infection","volume":"4","author":"Wong","year":"1997","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.puhe.2016.08.002_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hep.21040","article-title":"HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C","volume":"43","author":"Patel","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.puhe.2016.08.002_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"issue":"11","key":"10.1016\/j.puhe.2016.08.002_bib39","article-title":"Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"Shepherd","year":"2007","journal-title":"Health Technol Assess Winch Engl"},{"key":"10.1016\/j.puhe.2016.08.002_bib40","article-title":"Unit costs of health & social care 2013","author":"Personal Social Services Research Unit","year":"2013"},{"issue":"5","key":"10.1016\/j.puhe.2016.08.002_bib41","doi-asserted-by":"crossref","first-page":"e97317","DOI":"10.1371\/journal.pone.0097317","article-title":"The hepatitis C cascade of care: identifying priorities to improve clinical outcomes","volume":"9","author":"Linas","year":"2014","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.puhe.2016.08.002_bib42","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.puhe.2016.08.002_bib43","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.puhe.2016.08.002_bib44","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.puhe.2016.08.002_bib45","doi-asserted-by":"crossref","first-page":"e0125846","DOI":"10.1371\/journal.pone.0125846","article-title":"Assessing the long-term impact of treating hepatitis C virus (HCV)-Infected people who inject drugs in the UK and the relationship between treatment uptake and efficacy on future infections","volume":"10","author":"Bennett","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.puhe.2016.08.002_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.puhe.2016.08.002_bib47","article-title":"Barriers and facilitators to hepatitis C treatment for people who inject drugs","author":"World Health Organization","year":"2012","journal-title":"A Qual study"},{"issue":"8","key":"10.1016\/j.puhe.2016.08.002_bib48","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","article-title":"Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C","volume":"14","author":"Townsend","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.puhe.2016.08.002_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350616301986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350616301986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T11:58:26Z","timestamp":1718798306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033350616301986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":49,"alternative-id":["S0033350616301986"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2016.08.002","relation":{},"ISSN":["0033-3506"],"issn-type":[{"value":"0033-3506","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences","name":"articletitle","label":"Article Title"},{"value":"Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.puhe.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}